Contribution of bone metabolism features in carotid/femoral plaque formation and arterial wall thickening (IMT>0.90 mm) among patients with SLE
| Plaque | No plaque | P value | IMT >0.9 mm | IMT ≤0.9 mm | P value | |
| Bone metabolism markers | ||||||
| PTH (mean±SD), pg/mL | 51.1±27.7 | 37.4±18.4 | 0.003 | 54.0±32.7 | 40.0±18.3 | 0.02 |
| Hyperparathyroidism (>65 pg/mL) (%) | 25.0 | 3.9 | 0.002 | 27 | 8.7 | 0.012 |
| 25-OHD (mean±SD), ng/mL | 20.2±9.4 | 20.2±8.4 | ns | 20.0±9.7 | 19.9±8.7 | ns |
| Vitamin D deficiency (<20 ng/mL) (%) | 50.8 | 50.9 | ns | 58.3 | 51.4 | ns |
| Ca (mean±SD), mmol/L | 9.4±0.5 | 9.4±0.4 | ns | 9.4±0.5 | 9.4±0.4 | ns |
| P (mean±SD), mmol/L | 3.4±0.6 | 3.3±0.6 | ns | 3.5±0.6 | 3.3±0.6 | ns |
| Ca urine (mean±SD), g/24 hours | 0.13±0.13 | 0.16±0.20 | ns | 0.09±0.06 | 0.16±0.19 | ns |
| P urine (mean±SD), g/24 hours | 0.65±0.37 | 0.58±0.32 | ns | 0.60±0.25 | 0.64±0.40 | ns |
| CTX (mean±SD), ng/mL | 0.35±0.28 | 0.39±0.28 | ns | 0.38±0.34 | 0.35±0.25 | ns |
| NTX (mean±SD) ng/mL | 36.8±29.3 | 35.6±27.2 | ns | 38.4±33.7 | 35.4±26.5 | ns |
| Disorders of bone metabolism | ||||||
| Osteoporosis (%) | 25.4 | 4.9 | 0.007 | 26.3 | 8.8 | 0.04 |
| Osteopenia (%) | 27.1 | 22.0 | ns | 26.3 | 8.6 | ns |
| Osteoporotic fractures (%) | 6.5 | 1.8 | ns | 6.1 | 3.9 | ns |
| Osteoporosis treatment | ||||||
| Calcium supplementation (%) | 74.0 | 75.4 | ns | 75.5 | 76.3 | ns |
| Vitamin D supplementation (%) | 77.9 | 75.0 | ns | 81.6 | 76 | ns |
| Bisphosphonates (%) | 43.4 | 26.3 | 0.04 | 39.6 | 34.2 | ns |
CTX, C-terminal telopeptide of type I collagen; IMT, intima–media thickness; ns, non-significant; NTX, N-terminal telopeptide of type I collagen; 25-OHD, 25(OH) vitamin D3; PTH, parathormone.